Bio-Thera expands Intas pact to bring golimumab biosimilar to India 

Key Highlights: 

• Bio-Thera Solutions has expanded its partnership with Intas Pharmaceuticals through an exclusive commercialization and licensing agreement for India, covering its proposed golimumab biosimilar BAT2506. This marks Bio-Thera’s first biosimilar partnership in the Indian market 

• BAT2506 references Simponi (golimumab), a TNF-α targeting monoclonal antibody used across multiple inflammatory conditions including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. By inhibiting TNF-α, the therapy reduces key inflammatory markers such as CRP, IL-6, ICAM-1, MMP-3, and VEGF 

• The expanded collaboration combines Bio-Thera’s development capabilities with Intas’ commercial strength in India, aiming to improve access to high-quality biosimilars in immunology. The deal also strengthens Intas’ biologics portfolio and reflects both companies’ focus on advancing affordable, science-driven therapies in high-demand markets like India 

Implications: 

The expanded BAT2506 deal gives Intas a late‑stage TNF‑α biosimilar in a broad immunology class, reinforcing its biologics presence in rheumatology and gastroenterology while allowing Bio‑Thera to enter India via a partner with strong domestic reach. 
For India, bringing a Simponi‑referenced golimumab biosimilar under this alliance should, over time, widen access to advanced anti‑TNF therapy and intensify price and access pressure across the domestic immunology market, particularly in high‑burden indications like rheumatoid arthritis and ulcerative colitis.  

Source:  PRnewswire